{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:49Z","timestamp":1791908209593,"version":"4.3.4"},"reference-count":148,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1053\/j.gastro.2018.09.058","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T18:06:49Z","timestamp":1539886009000},"page":"461-476.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Pathogenesis of and New Therapies for Hepatitis D"],"prefix":"10.1053","volume":"156","author":[{"given":"Christopher","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2018.09.058_bib1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver\u00a0and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.09.058_bib2","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1073\/pnas.77.10.6124","article-title":"delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees","volume":"77","author":"Rizzetto","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2018.09.058_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/infdis\/141.5.590","article-title":"Transmission of the hepatitis B virus-associated delta antigen to chimpanzees","volume":"141","author":"Rizzetto","year":"1980","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/323508a0","article-title":"Structure, sequence and expression of the hepatitis delta (delta) viral genome","volume":"323","author":"Wang","year":"1986","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2018.09.058_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11894-013-0365-x","article-title":"Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery","volume":"16","author":"Noureddin","year":"2014","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1053\/j.gastro.2018.09.058_bib6","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1128\/iai.43.3.1000-1005.1984","article-title":"Delta hepatitis agent: structural and antigenic properties of the delta-associated particle","volume":"43","author":"Bonino","year":"1984","journal-title":"Infect Immun"},{"key":"10.1053\/j.gastro.2018.09.058_bib7","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1128\/JVI.76.8.3709-3719.2002","article-title":"Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA","volume":"76","author":"Gudima","year":"2002","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib8","first-page":"151","article-title":"Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades?","volume":"307","author":"Deny","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1053\/j.gastro.2018.09.058_bib9","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.29574","article-title":"Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains","volume":"66","author":"Le Gal","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1128\/JVI.78.5.2537-2544.2004","article-title":"Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades","volume":"78","author":"Radjef","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/viro.1997.8644","article-title":"Geographic distribution and genetic variability of hepatitis delta virus genotype I","volume":"234","author":"Shakil","year":"1997","journal-title":"Virology"},{"key":"10.1053\/j.gastro.2018.09.058_bib12","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1093\/nar\/19.19.5439","article-title":"Complete nucleotide sequence of hepatitis delta virus RNA in Japan","volume":"19","author":"Imazeki","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"10.1053\/j.gastro.2018.09.058_bib13","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1099\/0022-1317-82-11-2709","article-title":"Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia","volume":"82","author":"Ivaniushina","year":"2001","journal-title":"J\u00a0Gen Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1096-9071(199606)49:2<145::AID-JMV12>3.0.CO;2-D","article-title":"Characterization of a new genotype II hepatitis delta virus from Taiwan","volume":"49","author":"Lee","year":"1996","journal-title":"J\u00a0Med Virol"},{"issue":"Pt. 5","key":"10.1053\/j.gastro.2018.09.058_bib15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1099\/0022-1317-79-5-1105","article-title":"Characterization and phylogenetic analysis of a novel hepatitis D virus strain discovered by restriction fragment length polymorphism analysis","volume":"79","author":"Wu","year":"1998","journal-title":"J\u00a0Gen Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib16","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1099\/0022-1317-82-9-2183","article-title":"Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela","volume":"82","author":"Nakano","year":"2001","journal-title":"J\u00a0Gen Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib17","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1073\/pnas.90.19.9016","article-title":"A\u00a0genotype of hepatitis D virus that occurs in northern South America","volume":"90","author":"Casey","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2018.09.058_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4269\/ajtmh.2006.75.475","article-title":"HDV genotypes in the Western Brazilian Amazon region: a preliminary report","volume":"75","author":"Parana","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1053\/j.gastro.2018.09.058_bib19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/(SICI)1096-9071(199908)58:4<366::AID-JMV8>3.0.CO;2-X","article-title":"Hepatitis delta virus genotype IIb predominates in an endemic area, Okinawa, Japan","volume":"58","author":"Sakugawa","year":"1999","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib20","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3201\/eid1209.060112","article-title":"Eighth major clade for hepatitis delta virus","volume":"12","author":"Le Gal","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib21","first-page":"123","article-title":"Control of ADAR1 editing of hepatitis delta virus RNAs","volume":"353","author":"Casey","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1053\/j.gastro.2018.09.058_bib22","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1598578","article-title":"Identification of a prenylation site in delta virus large antigen","volume":"256","author":"Glenn","year":"1992","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.09.058_bib23","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1128\/JVI.76.20.10465-10472.2002","article-title":"A\u00a0prenylation inhibitor prevents production of infectious hepatitis delta virus particles","volume":"76","author":"Bordier","year":"2002","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/jvi.58.3.945-950.1986","article-title":"Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope","volume":"58","author":"Bonino","year":"1986","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib25","first-page":"113","article-title":"The role of the HBV envelope proteins in the HDV replication cycle","volume":"307","author":"Sureau","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1053\/j.gastro.2018.09.058_bib26","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib27","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/JVI.01758-07","article-title":"Transcription of hepatitis delta virus RNA by RNA polymerase II","volume":"82","author":"Chang","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0092-8674(90)90516-H","article-title":"Hepatitis delta virus: cis and trans functions required for replication","volume":"61","author":"Taylor","year":"1990","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2018.09.058_bib29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1128\/jvi.64.3.1021-1027.1990","article-title":"A\u00a0specific base transition occurs on replicating hepatitis delta virus RNA","volume":"64","author":"Luo","year":"1990","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib30","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1128\/jvi.65.5.2357-2361.1991","article-title":"Trans-dominant inhibition of human hepatitis delta virus genome replication","volume":"65","author":"Glenn","year":"1991","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib31","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1128\/jvi.64.10.5066-5069.1990","article-title":"Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication","volume":"64","author":"Chao","year":"1990","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/JCM.02142-07","article-title":"Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa","volume":"46","author":"Makuwa","year":"2008","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1053\/j.gastro.2018.09.058_bib33","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/JCM.01822-10","article-title":"High prevalence and predominance of hepatitis delta virus genotype 1 infection in Cameroon","volume":"49","author":"Foupouapouognigni","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1053\/j.gastro.2018.09.058_bib34","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/JCM.02297-13","article-title":"Characterization of hepatitis delta virus in sub-Saharan Africa","volume":"52","author":"Andernach","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1053\/j.gastro.2018.09.058_bib35","first-page":"448","article-title":"Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: a cross sectional study","volume":"67","author":"Lunel-Fabiani","year":"2013","journal-title":"J\u00a0Infect"},{"key":"10.1053\/j.gastro.2018.09.058_bib36","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jmv.23336","article-title":"Prevalence, risk factors, and molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in Mauritania","volume":"84","author":"Mansour","year":"2012","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib37","doi-asserted-by":"crossref","first-page":"e8210","DOI":"10.5812\/hepatmon.8210","article-title":"Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis","volume":"13","author":"Amini","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1053\/j.gastro.2018.09.058_bib38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.5812\/kowsar.1735143X.4213","article-title":"Clinical features and\u00a0seroepidemiology of anti-HDV antibody in patients with chronic hepatitis B virus infection in Iran: a meta-analysis","volume":"11","author":"Amini","year":"2011","journal-title":"Hepat Mon"},{"key":"10.1053\/j.gastro.2018.09.058_bib39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4269\/ajtmh.2006.75.365","article-title":"Hepatitis delta virus infection in mongolia: analyses of geographic distribution, risk factors, and disease severity","volume":"75","author":"Davaalkham","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1053\/j.gastro.2018.09.058_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jmv.20482","article-title":"High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia","volume":"77","author":"Tsatsralt-Od","year":"2005","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib41","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/hep.28957","article-title":"A\u00a0novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib42","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/jmv.23524","article-title":"Epidemiology of hepatitis D in patients infected with hepatitis B virus in bucharest: a cross-sectional study","volume":"85","author":"Popescu","year":"2013","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib43","first-page":"106","article-title":"[Prevalence of seronegative hepatitis D among patients with chronic viral hepatitis B]","author":"Semenov","year":"2012","journal-title":"Zh Mikrobiol Epidemiol Immunobiol"},{"key":"10.1053\/j.gastro.2018.09.058_bib44","doi-asserted-by":"crossref","first-page":"e78094","DOI":"10.1371\/journal.pone.0078094","article-title":"High prevalence and significance of hepatitis D virus infection among treatment-naive HBsAg-positive patients in Northern Vietnam","volume":"8","author":"Sy","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.09.058_bib45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1590\/S0037-86822012000600007","article-title":"Hepatitis D virus infection in the Western Brazilian Amazon\u2014far from a vanishing disease","volume":"45","author":"Braga","year":"2012","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1053\/j.gastro.2018.09.058_bib46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2334-14-94","article-title":"Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the Western Amazon region, North Brazil","volume":"14","author":"Crispim","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib47","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0168-8278(05)80629-4","article-title":"Incidence and risk factors of acute Delta hepatitis in Italy: results from a national surveillance system. SEIEVA Collaborating Group","volume":"21","author":"Stroffolini","year":"1994","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1440-1746.1997.tb00424.x","article-title":"Review: hepatitis delta","volume":"12","author":"Hadziyannis","year":"1997","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1440-1746.1997.tb00363.x","article-title":"Decreasing prevalence of hepatitis D virus infection","volume":"12","author":"Hadziyannis","year":"1997","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib50","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1053\/jhep.2000.17711","article-title":"Chronic hepatitis D: a vanishing disease? An Italian multicenter study","volume":"32","author":"Gaeta","year":"2000","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib51","first-page":"521","article-title":"A\u00a0re-assessment of the epidemiology and patient characteristics of hepatitis D virus infection in inner city London","volume":"66","author":"William Tong","year":"2013","journal-title":"J\u00a0Infect"},{"key":"10.1053\/j.gastro.2018.09.058_bib52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcv.2013.11.016","article-title":"Increasing prevalence of HDV\/HBV infection over 15 years in France","volume":"59","author":"Servant-Delmas","year":"2014","journal-title":"J\u00a0Clin Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib53","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/hep.21590","article-title":"Hepatitis D virus infection\u2014not a vanishing disease in Europe!","volume":"45","author":"Wedemeyer","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/jgh.12217","article-title":"Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California","volume":"28","author":"Gish","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virusres.2018.03.013","article-title":"Hepatitis D diagnostics: utilization and testing in the United States","volume":"250","author":"Safaie","year":"2018","journal-title":"Virus Res"},{"key":"10.1053\/j.gastro.2018.09.058_bib56","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","article-title":"Delta hepatitis within the Veterans Affairs Medical System in the United States: prevalence, risk factors, and outcomes","volume":"63","author":"Kushner","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1086\/655808","article-title":"Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users","volume":"202","author":"Kucirka","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib58","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/infdis\/jiy157","article-title":"Hepatitis D viremia among injection drug users in San Francisco","volume":"217","author":"Mahale","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib59","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1128\/jvi.63.10.4292-4297.1989","article-title":"Cloned hepatitis delta virus cDNA is infectious in the chimpanzee","volume":"63","author":"Sureau","year":"1989","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib60","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/jvi.65.3.1099-1104.1991","article-title":"Production of hepatitis\u00a0delta virus and suppression of helper hepatitis B virus in a human hepatoma cell line","volume":"65","author":"Wu","year":"1991","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib62","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0168-8278(91)90911-T","article-title":"Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection","volume":"12","author":"Colombo","year":"1991","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/00365548709032395","article-title":"Hepatitis D virus (delta agent) superinfection in an endemic area of hepatitis B infection: immunopathologic and serologic findings","volume":"19","author":"Lee","year":"1987","journal-title":"Scand J Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib64","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF01643238","article-title":"Interaction between HDV and HBV infection in HBsAg-chronic carriers","volume":"19","author":"Sagnelli","year":"1991","journal-title":"Infection"},{"key":"10.1053\/j.gastro.2018.09.058_bib65","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2009.10.036","article-title":"Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D","volume":"52","author":"Schaper","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib66","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.1840130508","article-title":"Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen","volume":"13","author":"Cole","year":"1991","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib67","first-page":"315","article-title":"Pathologic and ultrastructural changes of acute and chronic delta hepatitis in an experimentally infected chimpanzee","volume":"122","author":"Govindarajan","year":"1986","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2018.09.058_bib68","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/hep.1840030603","article-title":"Histologic studies of severe delta agent infection in Venezuelan Indians","volume":"3","author":"Popper","year":"1983","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib69","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1099\/vir.0.011239-0","article-title":"Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha\/beta interferon-inducible MxA gene","volume":"90","author":"Williams","year":"2009","journal-title":"J\u00a0Gen Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib70","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4254\/wjh.v5.i12.666","article-title":"Life cycle and pathogenesis of hepatitis D virus: a review","volume":"5","author":"Abbas","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib71","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF01644544","article-title":"Clinical features of hepatitis delta virus infection in a northern Italian area","volume":"16","author":"Pasetti","year":"1988","journal-title":"Infection"},{"key":"10.1053\/j.gastro.2018.09.058_bib72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(82)90976-X","article-title":"Multicentre study of prevalence of HBV-associated delta infection and liver disease in drug-addicts","volume":"1","author":"Raimondo","year":"1982","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2018.09.058_bib73","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1055\/s-0032-1323628","article-title":"Clinical features of hepatitis D","volume":"32","author":"Farci","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib74","first-page":"221","article-title":"Hepatitis D: virology, clinical and epidemiological aspects","volume":"63","author":"Rizzetto","year":"2000","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1053\/j.gastro.2018.09.058_bib75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2893.2010.01353.x","article-title":"Natural history and treatment of chronic delta hepatitis","volume":"17","author":"Yurdaydin","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.09.058_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2893.2000.00195.x","article-title":"Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections","volume":"7","author":"Mathurin","year":"2000","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.09.058_bib77","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0676.1989.tb00404.x","article-title":"Influence of HDV infection on clinical, biochemical and histological presentation of HBsAg positive chronic hepatitis","volume":"9","author":"Sagnelli","year":"1989","journal-title":"Liver"},{"key":"10.1053\/j.gastro.2018.09.058_bib78","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/infdis\/155.5.931","article-title":"Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B","volume":"155","author":"Fattovich","year":"1987","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.13834","article-title":"Noninvasive markers for staging fibrosis in chronic delta hepatitis","volume":"45","author":"Takyar","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.09.058_bib80","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jmv.21078","article-title":"The increasing prevalence of hepatitis delta virus (HDV) infection in South London","volume":"80","author":"Cross","year":"2008","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib81","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4254\/wjh.v7.i5.777","article-title":"Hepatitis D and hepatocellular carcinoma","volume":"7","author":"Abbas","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib82","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jnci\/djs168","article-title":"A\u00a0population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma","volume":"104","author":"Ji","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2018.09.058_bib83","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/hep.1840070627","article-title":"The epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan","volume":"7","author":"Toukan","year":"1987","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib84","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A\u00a028-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.09.058_bib85","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: a long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib86","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","article-title":"Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients","volume":"130","author":"Su","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.09.058_bib87","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/hep.1840080631","article-title":"Serial passage of hepatitis delta virus in chronic hepatitis B virus carrier chimpanzees","volume":"8","author":"Ponzetto","year":"1988","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jmv.1890130109","article-title":"Sensitive enzyme immunoassay for the detection of delta antigen and anti-delta, using serum as the delta antigen source","volume":"13","author":"Shattock","year":"1984","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib89","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1128\/jcm.29.9.1873-1876.1991","article-title":"Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies","volume":"29","author":"Shattock","year":"1991","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1053\/j.gastro.2018.09.058_bib90","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(87)92090-3","article-title":"Serological response to the hepatitis delta virus in hepatitis D","volume":"1","author":"Aragona","year":"1987","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2018.09.058_bib91","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/s-0032-1323627","article-title":"Hepatitis delta virus diagnosis","volume":"32","author":"Olivero","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib92","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.28772","article-title":"First international external quality assessment for hepatitis delta virus RNA\u00a0quantification in plasma","volume":"64","author":"Le Gal","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib93","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/JCM.02027-16","article-title":"Performance characteristics of a new consensus commercial kit for hepatitis d virus RNA viral load quantification","volume":"55","author":"Le Gal","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1053\/j.gastro.2018.09.058_bib94","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0016-5085(95)90453-0","article-title":"Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction","volume":"108","author":"Wu","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.09.058_bib95","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib96","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2018.09.058_bib98","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJM199401133300202","article-title":"Treatment of chronic hepatitis D with interferon alfa-2a","volume":"330","author":"Farci","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.09.058_bib99","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.09.058_bib100","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib101","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib102","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.09.058_bib103","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/hep.27357","article-title":"Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling","volume":"60","author":"Guedj","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib104","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0016-5085(99)70409-9","article-title":"Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy","volume":"117","author":"Lau","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.09.058_bib105","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.cgh.2015.05.029","article-title":"Association between level of hepatitis D virus RNA at WEEK 24 of pegylated interferon therapy and outcome","volume":"13","author":"Keskin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/cid\/cis459","article-title":"Entecavir treatment of chronic hepatitis D","volume":"55","author":"Kabacam","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib107","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.510300217","article-title":"Lamivudine for chronic delta hepatitis","volume":"30","author":"Lau","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib108","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs lamivudine\u00a0+ interferon vs interferon","volume":"15","author":"Yurdaydin","year":"2008","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.09.058_bib109","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.09.058_bib110","first-page":"222A","article-title":"96 weeks of pegylated-interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study","volume":"58","author":"Wedemeyer","year":"2013","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib111","doi-asserted-by":"crossref","first-page":"e101002","DOI":"10.1371\/journal.pone.0101002","article-title":"Anti-HDV IgM as a marker of disease activity in hepatitis delta","volume":"9","author":"Wranke","year":"2014","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.09.058_bib112","doi-asserted-by":"crossref","first-page":"349575","DOI":"10.1155\/2011\/349575","article-title":"Interferon lambda: a new sword in cancer immunotherapy","volume":"2011","author":"Lasfar","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1053\/j.gastro.2018.09.058_bib113","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","article-title":"Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in\u00a0vivo","volume":"80","author":"Ank","year":"2006","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib114","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","article-title":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B)","volume":"64","author":"Chan","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib115","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1186\/s40064-016-2920-z","article-title":"A\u00a0randomized, controlled study of peginterferon lambda-1a\/ribavirin \u00b1 daclatasvir for hepatitis C virus genotype 2 or 3","volume":"5","author":"Foster","year":"2016","journal-title":"Springerplus"},{"key":"10.1053\/j.gastro.2018.09.058_bib116","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1038\/s41598-017-03946-9","article-title":"Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV\/HDV infected humanized mice","volume":"7","author":"Giersch","year":"2017","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2018.09.058_bib117","first-page":"496A","article-title":"A\u00a0phase 2 randomized clinical trial to evaluate the safety and efficacy of pegylated intereron lambda monotherapy in patients with chronic hepatitis delta virus infection. Interim results from the LIMT HDV study","volume":"66","author":"Hamid","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib118","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.21112","article-title":"Characterization of a hepatitis B and hepatitis delta virus receptor binding site","volume":"43","author":"Engelke","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib119","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","article-title":"Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein","volume":"79","author":"Gripon","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib120","doi-asserted-by":"crossref","first-page":"9786","DOI":"10.1128\/JVI.79.15.9786-9798.2005","article-title":"Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition","volume":"79","author":"Barrera","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib121","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0168-8278(15)30738-8","article-title":"Myrcludex-B inhibits establishment of HDV super-infection in HBV infected mice and reduces HDV viremia in stabily HBV\/HDV co-infected mice","volume":"62","author":"Volz","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib122","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib123","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib124","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.744","article-title":"The NTCP-inhibitor myrcludex B: effects on bile acid disposition and tenofovir pharmacokinetics","volume":"103","author":"Blank","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.09.058_bib125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"133","author":"Vaillant","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2018.09.058_bib126","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/AAC.00279-08","article-title":"Amphipathic DNA polymers exhibit antiherpetic activity in\u00a0vitro and in\u00a0vivo","volume":"52","author":"Bernstein","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2018.09.058_bib127","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/135965350701200810","article-title":"Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression","volume":"12","author":"Guzman","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1053\/j.gastro.2018.09.058_bib128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.virol.2007.10.016","article-title":"Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers","volume":"372","author":"Lee","year":"2008","journal-title":"Virology"},{"key":"10.1053\/j.gastro.2018.09.058_bib129","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.gastro.2009.04.048","article-title":"Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry","volume":"137","author":"Matsumura","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.09.058_bib130","doi-asserted-by":"crossref","first-page":"e0140909","DOI":"10.1371\/journal.pone.0140909","article-title":"Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection","volume":"10","author":"Noordeen","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.09.058_bib131","doi-asserted-by":"crossref","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.09.058_bib132","first-page":"912A","article-title":"Initial follow-up results from the REP 301 trial: Safety and efficacy of REP2139-Ca and pegylated interferon alpha-2a in caucasian patients with chronic HBV\/HDV co-infection","volume":"64","author":"Bazinet","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib133","doi-asserted-by":"crossref","first-page":"s257","DOI":"10.1016\/S0168-8278(15)30148-3","article-title":"Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in Caucasian patients with chronic HBV\/HDV co-infection","volume":"62","author":"Bazinet","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib134","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1016\/S0168-8278(18)31266-2","article-title":"Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV\/HDV coinfection: 18 month follow-up results from the REP 301-LTF study","volume":"68","author":"Bazinet","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.20076","article-title":"HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice","volume":"39","author":"Wang","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib136","doi-asserted-by":"crossref","first-page":"9303","DOI":"10.1128\/JVI.72.11.9303-9306.1998","article-title":"Use of a prenylation inhibitor as a novel antiviral agent","volume":"72","author":"Glenn","year":"1998","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2018.09.058_bib137","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/jac\/dkg490","article-title":"Prenylation inhibitors: a novel class of antiviral agents","volume":"52","author":"Einav","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2018.09.058_bib138","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI17704","article-title":"In\u00a0vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus","volume":"112","author":"Bordier","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2018.09.058_bib139","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.gastro.2018.09.058_bib140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2133\/dmpk.DMPK-12-RG-057","article-title":"Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice","volume":"28","author":"Tomaru","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1053\/j.gastro.2018.09.058_bib141","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2018.09.058_bib142","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.09.058_bib143","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0168-8278(17)30327-6","article-title":"A\u00a0phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study","volume":"66","author":"Yurdaydin","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib144","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(17)30464-6","article-title":"A\u00a0phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis - end of study results from the LOWR HDV-3 study","volume":"66","author":"Koh","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib145","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(17)30310-0","article-title":"A\u00a0phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study","volume":"66","author":"Wedemeyer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.09.058_bib146","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ijc.2910390303","article-title":"Delta agent and the etiology of hepatocellular carcinoma","volume":"39","author":"Trichopoulos","year":"1987","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2018.09.058_bib147","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/BF01297460","article-title":"Role of hepatitis delta virus infection in hepatocellular carcinoma","volume":"36","author":"Verme","year":"1991","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2018.09.058_bib148","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1440-1746.1993.tb01543.x","article-title":"Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan","volume":"8","author":"Tamura","year":"1993","journal-title":"J\u00a0Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851835162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851835162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:21:15Z","timestamp":1758036075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650851835162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":148,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S001650851835162X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2018.09.058","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis of and New Therapies for Hepatitis D","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2018.09.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute","name":"copyright","label":"Copyright"}]}}